tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Andreas Argyrides, 69 are a BUY (79.31%), 14 are a HOLD (16.09%), 4 are a SELL (4.6%).
Analyst Andreas Argyrides, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 29.5% that have a potential upside of 40.49% achieved within 127 days.
Andreas Argyrides’s has documented 172 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on KROS, Keros Therapeutics at 16-Dec-2024.
Analyst best performing recommendations are on RGNX (REGENXBIO).
The best stock recommendation documented was for RGNX (REGENXBIO) at 2/28/2024. The price target of $21 was fulfilled within 2 days with a profit of $1.1 (5.53%) receiving and performance score of 27.64.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$35
$27.38 (359.32%)
$20
10 days ago
(11-Dec-2024)
4/10 (40%)
$25.88 (283.77%)
50
Buy
$52
$44.38 (582.41%)
$52
1 months 1 days ago
(20-Nov-2024)
0/8 (0%)
$42.44 (443.93%)
Buy
$22
$14.38 (188.71%)
1 months 6 days ago
(15-Nov-2024)
1/3 (33.33%)
$12.06 (121.33%)
47
Buy
$18
$10.38 (136.22%)
$45
2 months 11 days ago
(10-Oct-2024)
0/5 (0%)
$8.71 (93.76%)
Buy
$55
$47.38 (621.78%)
9 months 14 days ago
(07-Mar-2024)
2/7 (28.57%)
$31.77 (136.76%)
74
Which stock is Andreas Argyrides is most bullish on?
Which stock is Andreas Argyrides is most reserved on?
What Year was the first public recommendation made by Andreas Argyrides?
